Our results of Sarm1 genetic inactivation advance white matter degeneration as a tractable therapeutic target for TBI and chronic traumatic encephalopathy, with potential application to other neurodegenerative diseases including Alzheimer’s disease and multiple sclerosis [4, 15, 17, 73]. This evidence concerns the gene SARM1 and early-onset autosomal dominant Alzheimer disease.